First Trust Direct Indexing L.P. Grows Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

First Trust Direct Indexing L.P. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,288 shares of the medical equipment provider’s stock after buying an additional 669 shares during the period. First Trust Direct Indexing L.P.’s holdings in Intuitive Surgical were worth $4,106,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ISRG. Provence Wealth Management Group acquired a new position in Intuitive Surgical during the 4th quarter worth about $276,000. Portside Wealth Group LLC lifted its position in shares of Intuitive Surgical by 8.2% during the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Intuitive Surgical by 58.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after purchasing an additional 3,054 shares during the period. Public Employees Retirement System of Ohio grew its holdings in shares of Intuitive Surgical by 5.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock valued at $64,531,000 after purchasing an additional 9,869 shares in the last quarter. Finally, HCR Wealth Advisors increased its stake in Intuitive Surgical by 26.3% during the 4th quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after buying an additional 217 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.9 %

Shares of ISRG traded down $4.00 during trading hours on Thursday, reaching $434.81. The company had a trading volume of 826,374 shares, compared to its average volume of 1,473,994. The company has a market capitalization of $154.23 billion, a price-to-earnings ratio of 78.49, a PEG ratio of 5.67 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $448.10. The firm has a 50 day simple moving average of $407.60 and a 200-day simple moving average of $385.43.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period last year, the firm earned $1.00 EPS. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Robert W. Baird dropped their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Citigroup lifted their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. BTIG Research upped their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price on the stock. Finally, Evercore ISI boosted their price target on shares of Intuitive Surgical from $385.00 to $425.00 and gave the stock an “in-line” rating in a report on Tuesday. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $404.79.

Insiders Place Their Bets

In other news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total value of $589,484.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 239 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $416.60, for a total transaction of $99,567.40. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,293,799.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total transaction of $589,484.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,956 shares of company stock worth $6,927,011. 0.80% of the stock is owned by corporate insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.